BPTH.OOTC
- Bio-Path Holdings, Inc.
報價延遲最少15分鐘:2025/07/03 11:21 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
0.161 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
0.36/-1.42
|
|
企業價值
1.45M
|
| 資產負債 |
|
每股賬面淨值
-0.31
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||
|
||||||||||||||||
報價延遲最少15分鐘：2025/07/03 11:21 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Bio-Path Holdings Inc is a clinical and preclinical stage oncology-focused RNAi nanoparticle drug development company. It is engaged in utilizing a novel technology that achieves systemic delivery for target-specific protein inhibition forany gene product that is over-expressed in disease. The company's drug candidate, prexigebersen, is in the efficacy portion of a Phase 2 clinical trial for acute myeloid leukemia (AML) in combination with low-dose cytarabine (LDAC) and combination with decitabine. The other drugs of the company are BP1002, BP1003, BP1001-A, and DNABILIZE. |